1. Readthrough of ACTN3 577X nonsense mutation produces full-length α-actinin-3 protein.
- Author
-
Harada, Nagakatsu, Hatakeyama, Adzumi, Okuyama, Maiko, Miyatake, Yumiko, Nakagawa, Tadahiko, Kuroda, Masashi, Masumoto, Saeko, Tsutsumi, Rie, Nakaya, Yutaka, and Sakaue, Hiroshi
- Subjects
- *
ACTININ , *MUSCLE cells , *RNA splicing , *GENE expression , *MESSENGER RNA , *MICROFILAMENT proteins - Abstract
The ACTN3 gene encodes α-actinin-3 protein, which stabilizes the contractile apparatus at the Z-line in skeletal muscle cell fast fibers. A nonsense mutation of the arginine (R) at the codon for amino acid 577 of the ACTN3 gene generates a premature termination codon (PTC) and produces the R577X polymorphism in humans (X specifies translational termination). The ACTN3 577X genotype abolishes α-actinin-3 protein production due to targeted degradation of the mutant transcript by the cellular nonsense-mediated mRNA decay (NMD) system, which requires mRNA splicing. In humans, α-actinin-3 deficiency can decrease sprinting and power performance as well as skeletal muscle mass and strength. Here we investigated whether suppression of the in-frame PTC induced by treatment with the aminoglycosides gentamicin and G418 that promote termination codon readthrough could allow production of full-length α-actinin-3 protein from ACTN3 577X. We constructed expression plasmids encoding mature mRNA that lacks introns or pre-mRNA, which carries introns for the ACTN3 577X gene (X and X pre , respectively) and transfected the constructs into HEK293 cells. Similar constructs for the ACTN3 577R gene were used as controls. HEK293 cells carrying the X gene, but not the X pre gene, expressed exogenous truncated α-actinin-3 protein, indicating NMD-mediated suppression of exogenous X pre expression. Cells treated with aminoglycosides produced exogenous full-length α-actinin-3 protein in X-transfected cells, but not in X pre -transfected cells. The NMD inhibitor caffeine prevented suppression of X pre expression and thereby induced production of full-length α-actinin-3 protein in the presence of aminoglycoside. Together these results indicate that the ACTN3 R577X polymorphism could be a novel target for readthrough therapy, which may affect athletic and muscle performance in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF